Logo

Boehringer Ingelheim and Zealand Pharma to Initiate P-II Study of BI 456906 for Obesity and Diabetes

Share this

Boehringer Ingelheim and Zealand Pharma to Initiate P-II Study of BI 456906 for Obesity and Diabetes

Shots:

  • The advancement of BI 456906 to P-II study is based on the safety and tolerability and a wt. loss in individuals with a BMI up to 40 kg/m2 - which will be a PBO controlled proof of concept study in patients with obesity and type 2 diabetes
  • BI in-licensed two candidates from Zealand for GLP-1/glucagon dual agonist- Zealand will receive ~$21M out of ~$399M milestones at the initiation of P-II study with royalties on sales. For long-acting amylin analog- Zealand to receive ~$309M milestones and royalties on sales
  • BI 456906 (qw) is dual-acting GLP-1/glucagon peptide- derived from the natural gut hormone oxyntomodulin activating both the GLP-1 and glucagon receptors and is a part of BI’s obesity and diabetes portfolio

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Multivu


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions